# Enbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance]

> **NCT01145352** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 113 (actual)

## Conditions studied

- Juvenile Idiopathic Arthritis

## Interventions

- **DRUG:** Etanercept (genetical recombination)

## Key facts

- **NCT ID:** NCT01145352
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2014-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01145352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01145352, "Enbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance]". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01145352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*